GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Long-Term Capital Lease Obligation

Akums Drugs and Pharmaceuticals (NSE:AKUMS) Long-Term Capital Lease Obligation : ₹653 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Long-Term Capital Lease Obligation?

Akums Drugs and Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹653 Mil.

Akums Drugs and Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (₹708 Mil) to Mar. 2024 (₹679 Mil) and declined from Mar. 2024 (₹679 Mil) to Sep. 2024 (₹653 Mil).

Akums Drugs and Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Mar. 2022 (₹304 Mil) to Mar. 2023 (₹749 Mil) but then declined from Mar. 2023 (₹749 Mil) to Mar. 2024 (₹679 Mil).

Akums Drugs and Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Long-Term Capital Lease Obligation Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Long-Term Capital Lease Obligation
278.67 304.08 748.80 679.05

Akums Drugs and Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial - 748.80 708.19 679.05 653.32

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Akums Drugs and Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Long-Term Capital Lease Obligation
Comparable Companies
Traded in Other Exchanges
544222:India
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Website
https://www.akums.in
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines